Hepatology · 2026

Liver disease care in China,
world-class hepatology centres.

Cirrhosis workup, MAFLD/NAFLD optimization, autoimmune hepatitis, primary biliary cholangitis, fibrosis staging and HCC surveillance at Class A hepatology centres. Bilingual hepatology workup from $850.

$850–1,800

Hepatology workup

FibroScan, MRE, labs, imaging, bilingual report

Partner clinic quotes 2024

Class A

Top centres

Zhongshan, PUMC, Beijing You'an, Shanghai PHCC

NHC ratings

FibroScan

+ MRE available

Non-invasive fibrosis staging widely deployed

Centre programs

Resmetirom

MASH treatment

NMPA-approved 2024 (later than FDA but at lower cost)

NMPA approvals

Bilingual

Hepatology report

Standard discharge package + home-team handover

Service standard

No transplant

Editorial policy

We do not coordinate liver transplant in mainland China

Compliance

Tiers & pricing

Six tiers, transparent pricing.

Diagnostic

Comprehensive workup

Liver function, viral panel, autoimmune markers, fibrosis (FibroScan / MRE), imaging.

$850–1,800

Common

MAFLD / NAFLD optimization

Cardiometabolic optimization, structured nutrition, GLP-1 / SGLT-2 / pioglitazone selection, resmetirom for MASH F2-3.

Quoted on case

Specialist

Autoimmune hepatitis

Steroid + azathioprine / MMF induction, biologic add-on for steroid-refractory cases.

Workup + meds

Specialist

Primary biliary cholangitis (PBC)

Ursodeoxycholic acid (UDCA) first-line; obeticholic acid (OCA), elafibranor, seladelpar second-line where approved.

Workup + meds

Complex

Cirrhotic complications care

Variceal screening, portal hypertension management, HE workup, ascites and SBP prophylaxis.

Quoted on case

Oncology

HCC surveillance + treatment

AFP + ultrasound q6m, contrast imaging if positive, HCC pathway via cancer centre.

Quoted on case

Top hospitals

Six centres
open to international patients.

Shanghai

Zhongshan Hospital Hepatology 中山医院

China's leading hepatobiliary centre · MAFLD, viral, autoimmune programs · trial site

Beijing

PUMC Hepatology 北京协和医院

Academic hepatology · diagnostic excellence · rare and atypical liver disease

Beijing

Beijing You'an Hospital 北京佑安医院

Class A specialty · viral hepatitis, cirrhosis, HCC · hepatology trial leader

Shanghai

Shanghai Public Health Clinical Center 上海市公共卫生临床中心

Class A specialty · large hepatitis cohort · cirrhotic care + trials

Multi-city

United Family Hospitals 和睦家

JCI · routine liver workup · expat-focused English-first

Chengdu

West China Hospital Hepatology 华西医院

Class A · regional reference · complex hepatology + HCC

FAQ

Frequently asked questions.

Why China for liver disease?
Three reasons: (1) HBV expertise — with ~84M chronic HBV carriers, Chinese hepatology centres have unmatched experience in viral hepatitis and its complications; (2) MAFLD prevalence — fatty liver disease affects 30%+ of Chinese adults, driving deep clinical and trial pipelines for resmetirom (MGL-3196), pioglitazone, GLP-1s and novel agents; (3) Cost — comprehensive hepatology workup including FibroScan, MRE and labs runs $850–$1,800 vs $3,500–$8,500 at US academic centres.
What does a comprehensive workup include?
Standard 2–3 day pathway: full liver-function panel (ALT, AST, ALP, GGT, bilirubin, albumin, INR, AFP); HBV / HCV / HEV serology; autoimmune panel (ANA, ASMA, AMA, LKM, IgG / IgM / IgA); metabolic workup (HbA1c, lipid panel, ferritin, transferrin saturation, ceruloplasmin if young); FibroScan or MRE (magnetic resonance elastography) for fibrosis; abdominal ultrasound; contrast CT / MRI if lesion or cirrhosis; FibroTest / ELF if non-invasive fibrosis biomarkers preferred. Bilingual final report mapped to AASLD / EASL guidance.
What about MAFLD / NAFLD treatment?
Standard approach: cardiometabolic optimization (weight loss 7–10%+ for steatohepatitis improvement, fibrosis regression with 10%+); structured Mediterranean diet; structured aerobic + resistance training; statin if indicated for cardiovascular primary indication; GLP-1 / GIP agonists (semaglutide, tirzepatide — NMPA-approved with strong MASH activity); SGLT-2 inhibitors for diabetic patients; resmetirom (MGL-3196) NMPA-approved 2024 for MASH F2-3; pioglitazone in selected diabetic patients. Bariatric surgery referral for eligible patients.
What about autoimmune liver disease?
Autoimmune hepatitis: induction with prednisone ± azathioprine or MMF; steroid taper; long-term immunosuppression. PBC: UDCA first-line; OCA / elafibranor / seladelpar (second-line FXR/PPAR agonists, NMPA approval pace varies). PSC: no specific approved therapy beyond UDCA off-label; transplant referral for advanced disease (we do not coordinate liver transplant). IgG4-related cholangiopathy: steroid-responsive — diagnostic care valuable to distinguish from PSC. We coordinate diagnostic workup and medical management; complex transplant decisions are referred home.
Why don't you coordinate liver transplant?
Same editorial policy as for all transplants in mainland China — see our [kidney-care page](/kidney-care-china) for details. International scrutiny over organ-sourcing transparency in mainland China remains active; until international transplant community consensus changes, we do not coordinate liver, kidney, heart, lung or bone-marrow transplants in mainland China. Patients seeking transplant should consult their home transplant centre.
How does HCC surveillance fit in?
Cirrhotic patients of any aetiology and selected non-cirrhotic high-risk patients (HBV with family history; Asian male HBV > 40, Asian female HBV > 50) require AFP + ultrasound q6m surveillance per AASLD / EASL. Class A hepatology centres bundle this into long-term programs. If suspicious lesion: contrast-enhanced CT / MRI same-day, biopsy if needed, MDT review for resection / ablation / TACE / immunotherapy. NMPA-approved HCC therapy includes atezolizumab + bevacizumab, durvalumab + tremelimumab, lenvatinib, regorafenib at NMPA-listed pricing.

Send your liver labs
for a written hepatology plan.

Upload your liver function tests, fibrosis assessment, viral panel and any imaging. We return a written hepatology plan from a partner specialist — including diagnostic workup, treatment recommendation and HCC surveillance schedule.

This page is for general information only and does not constitute medical advice. We do not coordinate liver transplant in mainland China. Acute hepatic failure or signs of decompensation are emergencies — present to your nearest ED.